Anti-tumor necrosis factor α (TNF-α) biologic agents are used for treating refractory sarcoidosis. However, sarcoidosis-like epithelioid cell granulomas may develop during anti-TNFα treatment. A 63-year-old man suffering from rheumatoid arthritis was treated with oral methotrexate and methylprednisolone for 4 years. He subsequently started biweekly subcutaneous injections of certolizumab pegol. Three months later, light red follicular papules developed on his chest and they spread over the trunk and bilateral upper arms. Histopathology of a lesion showed a sharply demarcated noncaseating epithelioid cell granuloma with multi-nucleated giant cells in the upper perifollicular area. The follicular papules subsided following discontinuation of certolizumab pegol. Folliculitis-like lichenoid sarcoidosis should be included among the adverse cutaneous reactions of anti-TNF-α treatment.
Introduction
Anti-tumor necrosis factor α (TNF-α) therapy is effective for several immune-mediated inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel diseases, psoriasis, and sarcoidosis. However, anti-TNF-α agents may also paradoxically induce or exacerbate these inflammatory diseases. Herein, we present a case of paradoxical lichenoid sarcoidosis in a patient with rheumatoid arthritis who was treated with certolizumab pegol (CZP).
Case Report
A 63-year-old man had been suffering from rheumatoid arthritis for 4 years. He received oral methotrexate and methylprednisolone without satisfactory therapeutic response. Biweekly subcutaneous injection of CZP was added in September 2013. Three months later, he visited our clinic due to pruritic reddish eruptions on his chest. A physical examination revealed light red follicular papules that were approximately 2 mm in size on his chest. Topical and oral antibiotic therapies were not effective, and the skin lesions gradually spread over the trunk and bilateral upper arms ( Fig. 1a, b) . A skin biopsy of a papule disclosed a sharply demarcated non-caseating epithelioid cell granuloma with multi-nucleated giant cells in the upper perifollicular area. Considerable mononuclear lymphoid cells had infiltrated around the granuloma (Fig. 2 ). Neither Ziehl-Neelsen staining nor auramine staining identified any acid-fast bacilli. A blood test, chest roentgenographic examination, and computed tomography did not reveal any remarkable change. An ophthalmological examination did not reveal any signs of ocular sarcoidosis or tuberculosis (TB). The patient's serum angiotensinconverting enzyme level was normal. The tuberculin skin test and interferon-gamma release test (QuantiFERON ® TB-Gold) results were marginally positive (10 × 10 mm and 0.10 IU/ mL, respectively). These findings suggested the diagnosis of lichen scrofulosorum. We discontinued CZP and started anti-TB therapy. The follicular papules began to subside. However, at 8 weeks following the initiation of anti-TB therapy, exudative erythema developed with histopathological findings of epidermal spongiosis and massive dermal eosinophilic infiltration. A drug-induced lymphocyte stimulation test for rifampicin was positive and the anti-TB therapy was discontinued. During the course of these events, the patient's rheumatoid arthritis worsened with marked arthralgia, which urged us to re-initiate the CZP therapy. Several follicular papules reappeared again, but they improved with topical glucocorticoid therapy. Eight weeks after starting the second CZP treatment, the patient developed arrhythmia and CZP was discontinued. The follicular papules gradually subsided and did not develop again. We finally diagnosed the skin lesions as lichenoid sarcoidosis.
Discussion
The patient's follicular papules were initially suspected to be superficial bacterial folliculitis. However, histopathology of the lesion disclosed a non-caseating epithelioid cell granuloma in the upper dermal perifollicular area, suggesting the diagnosis of lichen scrofulosorum. This was excluded because: (1) the patient did not develop TB during the oral methotrexate and methylprednisolone therapy, suggesting that he did not have latent TB;
(2) TB bacilli were never detected in the skin lesions; (3) no obvious systemic TB developed after the re-initiation of CZP therapy; (4) after cessation of the CZP therapy, the follicular papules subsided without anti-TB drugs; and (5) the follicular papules responded to topical glucocorticoid treatment. These findings together with the histopathology led to the diagnosis of CZP-induced lichenoid sarcoidosis.
Sarcoidosis is a multi-organ chronic inflammatory disease characterized by noncaseating epithelioid cell granulomas. TNF-α is among the key cytokines of granuloma formation, and anti-TNF-α treatment has been shown to be effective for refractory sarcoidosis [1, 2] . More than 50 cases of anti-TNF-α therapy-associated sarcoidosis have been reported [1] . In approximately 75% of the cases, the clinical presentation was systemic, mainly respiratory symptoms, such as dyspnea, chest pain, and cough. So far, 17 cases, including ours, of cutaneous non-caseating "sarcoidosis-like" granulomas with or without visceral involvement have been described ( Table 1 ). The cutaneous manifestations include papules, nodules, plaques, subcutaneous masses, scar infiltration, and follicular papules (the current case). The time lapse between the initiation of anti-TNF-α treatment and the onset of sarcoidosis varies from 1 month to 4 years. However, in approximately half of the cases (9/17), granulomas developed within the first year of treatment.
In conclusion, we present the first case of rheumatoid arthritis with lichenoid sarcoidosis induced by the anti-TNF-α agent CPZ. The patient's skin lesions mimicked superficial folliculitis, which is relatively common in cases under immunosuppressive treatments. Folliculitis-like lichenoid sarcoidosis should also be considered in patients receiving anti-TNF-α treatment as adverse cutaneous reactions, especially when follicular papules do not respond to conventional anti-microbial treatment.
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